Skip to main content
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. — Investor Relations & Filings

Ticker · INKT ISIN · US6036931029 LEI · 529900Z7778N8ZY89B90 US Manufacturing
Open in API
Filings indexed 226 across all filing types
Latest filing 2021-10-14 Regulatory Filings
Country US United States of America
Listing US INKT

About MiNK Therapeutics, Inc.

https://www.minktherapeutics.com

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. The company's platform harnesses the dual properties of iNKT cells, which combine the potent cytotoxicity of natural killer (NK) cells with the lasting memory response of T cells to enhance both innate and adaptive immunity. Its lead product candidate, AGENT-797, is an off-the-shelf therapy administered without requiring lymphodepletion or HLA matching. It is currently in clinical trials for solid tumors, severe acute respiratory distress syndrome (ARDS), and Graft versus Host Disease (GvHD). MiNK is also developing a next-generation technology platform for engineered iNKT cells and bispecific iNKT cell engagers for precision targeting.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-10-14 English
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It includes details about the registrant, the securities to be registered, and references to a previously filed Registration Statement on Form S-1. The document is a regulatory filing related to securities registration and does not contain financial statements, management discussion, or other report content. It is not an announcement of a report but a formal registration document. Therefore, it fits best under Regulatory Filings (RNS). The document length is 3275 characters, which is short and typical for such filings, and it is not a report publication announcement or certification. Hence, the classification is RNS with high confidence.
2021-10-13 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effectiveness of a Registration Statement on Form S-1. It references securities regulations and underwriters' compliance but does not contain financial statements or detailed financial data. The document length is short (2122 characters) and is primarily a formal request related to a registration filing, not a financial report or announcement of voting results, management changes, or earnings. This type of document is best classified as a Regulatory Filing (RNS) because it is a compliance-related communication with the SEC that does not fit other specific categories.
2021-10-12 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from MiNK Therapeutics, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. This is a procedural correspondence related to a securities registration process, not a financial report, earnings release, or any other detailed filing. The document is short (1343 characters) and serves as a formal request rather than containing substantive financial data or report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2021-10-12 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A Registration Statement Amendment No. 1 filed with the SEC for MiNK Therapeutics, Inc. It is a preliminary prospectus related to an initial public offering (IPO) of common stock. The text includes detailed information about the offering, company overview, risk factors, use of proceeds, management discussion and analysis, business description, executive compensation, principal stockholders, and other IPO-related disclosures. This type of filing is a registration statement for securities offering under the Securities Act of 1933, not a financial report like an annual or quarterly report, nor an earnings release or management discussion standalone document. It is a capital markets filing related to fundraising and securities issuance. According to the classification definitions, updates on company fundraising or capital structure changes fall under Capital/Financing Update (CAP). Therefore, the correct classification is CAP with high confidence.
2021-10-12 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed letter from MiNK Therapeutics, Inc. to the SEC Division of Corporation Finance responding to a comment on their Draft Registration Statement on Form S-1. It discusses confidential treatment requests, valuation of common stock, option grants, and estimated IPO price range. The document is not a financial report like an Annual Report or Interim Report, nor is it a transcript, earnings release, or management report. It is a regulatory correspondence related to a registration statement filing and confidential treatment request under SEC rules. The content is regulatory in nature, addressing SEC staff comments and providing supplemental information for the registration process. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory submission and correspondence that does not fit other specific categories.
2021-09-24 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.